Financhill
Sell
34

ETNB Quote, Financials, Valuation and Earnings

Last price:
$8.57
Seasonality move :
-3.05%
Day range:
$8.37 - $8.82
52-week range:
$5.99 - $13.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.17x
Volume:
1.3M
Avg. volume:
1.8M
1-year change:
-35.65%
Market cap:
$1.3B
Revenue:
--
EPS (TTM):
-$3.43

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ETNB
89bio
-- -$0.76 -- -10.19% $27.55
AKRO
Akero Therapeutics
-- -$1.12 -- -16.23% $77.64
MDGL
Madrigal Pharmaceuticals
$97.8M -$4.12 -- -49.7% $401.67
MRNA
Moderna
$941.1M -$2.73 -19.37% -0.05% $54.14
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ETNB
89bio
$8.70 $27.55 $1.3B -- $0.00 0% --
AKRO
Akero Therapeutics
$44.88 $77.64 $3.6B -- $0.00 0% --
MDGL
Madrigal Pharmaceuticals
$342.44 $401.67 $7.6B -- $0.00 0% --
MRNA
Moderna
$34.71 $54.14 $13.4B -- $0.00 0% 4.21x
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
PTN
Palatin Technologies
$0.81 $7.00 $21.1M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ETNB
89bio
-- 2.587 -- --
AKRO
Akero Therapeutics
-- 3.401 -- --
MDGL
Madrigal Pharmaceuticals
13.48% 3.153 1.73% 5.79x
MRNA
Moderna
-- 0.488 -- 3.45x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
PTN
Palatin Technologies
-- -1.737 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ETNB
89bio
-- -$122M -- -- -- -$121.6M
AKRO
Akero Therapeutics
-- -$78M -- -- -- -$67.1M
MDGL
Madrigal Pharmaceuticals
$99.9M -$67M -55.1% -63.91% -54.12% -$104.7M
MRNA
Moderna
$217M -$1.2B -29.09% -29.09% -123.22% $303M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M

89bio vs. Competitors

  • Which has Higher Returns ETNB or AKRO?

    Akero Therapeutics has a net margin of -- compared to 89bio's net margin of --. 89bio's return on equity of -- beat Akero Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    AKRO
    Akero Therapeutics
    -- -$0.99 --
  • What do Analysts Say About ETNB or AKRO?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand Akero Therapeutics has an analysts' consensus of $77.64 which suggests that it could grow by 72.99%. Given that 89bio has higher upside potential than Akero Therapeutics, analysts believe 89bio is more attractive than Akero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    AKRO
    Akero Therapeutics
    9 0 0
  • Is ETNB or AKRO More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison Akero Therapeutics has a beta of -0.193, suggesting its less volatile than the S&P 500 by 119.294%.

  • Which is a Better Dividend Stock ETNB or AKRO?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Akero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or AKRO?

    89bio quarterly revenues are --, which are smaller than Akero Therapeutics quarterly revenues of --. 89bio's net income of -$118.4M is lower than Akero Therapeutics's net income of -$70M. Notably, 89bio's price-to-earnings ratio is -- while Akero Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus -- for Akero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
  • Which has Higher Returns ETNB or MDGL?

    Madrigal Pharmaceuticals has a net margin of -- compared to 89bio's net margin of -57.51%. 89bio's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -63.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    MDGL
    Madrigal Pharmaceuticals
    96.67% -$2.71 $872M
  • What do Analysts Say About ETNB or MDGL?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $401.67 which suggests that it could grow by 17.3%. Given that 89bio has higher upside potential than Madrigal Pharmaceuticals, analysts believe 89bio is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    MDGL
    Madrigal Pharmaceuticals
    9 2 0
  • Is ETNB or MDGL More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.403, suggesting its less volatile than the S&P 500 by 140.327%.

  • Which is a Better Dividend Stock ETNB or MDGL?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or MDGL?

    89bio quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $103.3M. 89bio's net income of -$118.4M is lower than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, 89bio's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    MDGL
    Madrigal Pharmaceuticals
    -- -- $103.3M -$59.4M
  • Which has Higher Returns ETNB or MRNA?

    Moderna has a net margin of -- compared to 89bio's net margin of -117.16%. 89bio's return on equity of -- beat Moderna's return on equity of -29.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    MRNA
    Moderna
    22.7% -$2.91 $10.9B
  • What do Analysts Say About ETNB or MRNA?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand Moderna has an analysts' consensus of $54.14 which suggests that it could grow by 55.97%. Given that 89bio has higher upside potential than Moderna, analysts believe 89bio is more attractive than Moderna.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    MRNA
    Moderna
    5 17 1
  • Is ETNB or MRNA More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

  • Which is a Better Dividend Stock ETNB or MRNA?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or MRNA?

    89bio quarterly revenues are --, which are smaller than Moderna quarterly revenues of $956M. 89bio's net income of -$118.4M is higher than Moderna's net income of -$1.1B. Notably, 89bio's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus 4.21x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    MRNA
    Moderna
    4.21x -- $956M -$1.1B
  • Which has Higher Returns ETNB or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to 89bio's net margin of -49.65%. 89bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About ETNB or NBY?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that 89bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe 89bio is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ETNB or NBY More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock ETNB or NBY?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or NBY?

    89bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. 89bio's net income of -$118.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, 89bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns ETNB or PTN?

    Palatin Technologies has a net margin of -- compared to 89bio's net margin of -2357.27%. 89bio's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About ETNB or PTN?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 764.09%. Given that Palatin Technologies has higher upside potential than 89bio, analysts believe Palatin Technologies is more attractive than 89bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    PTN
    Palatin Technologies
    0 0 0
  • Is ETNB or PTN More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock ETNB or PTN?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or PTN?

    89bio quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. 89bio's net income of -$118.4M is lower than Palatin Technologies's net income of -$2.4M. Notably, 89bio's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock